Usage:
For the treatment of diabetes and it can help to lose weight.
Advantages:
1) Our Sermaglutide API is in Pilot stage with production quantity 100g per batch.
2) We will get DMF documents in early 2023, and submit to FDA in the middle of 2023 for Sermaglutide API.
3) Our sermaglutide API and intermediates are produced in GMP condition workshop, with high purity 99% up, single impurity below 0.1% by HPLC.
4) Competitive price compares with the original Novo Nordisk for API.
5) Sermaglutide is a very new and good API for diabetes with very large market demand quantities.
6) Using advanced recombinant protease with Bio-enzyme technology to produce the intermediates of Sermaglutide (main chain and side chain).
|